Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Corso della Repubblica 79, 04100, Latina, Italy.
Drugs. 2018 Sep;78(14):1459-1479. doi: 10.1007/s40265-018-0980-9.
Pain is one of the most common symptoms among patients with end-stage renal disease (ESRD), and is often under recognized and not adequately managed in hemodialysis (HD) patients. Barriers to adequate pain management include poor awareness of the problem, insufficient medical education, fears of possible drug-related side effects, and common misconceptions about the inevitability of pain in elderly and HD patients. Caregivers working in HD should be aware of the possible consequences of inadequate pain assessment and management. Common pain syndromes in HD patients include musculoskeletal diseases and metabolic neuropathies, associated with typical intradialytic pain. Evaluating the etiology, nature, and intensity of pain is crucial for choosing the correct analgesic. A mechanism-based approach to pain management may result in a better outcome. Pharmacokinetic considerations on clearance alterations and possible toxicity in patients with ESRD should drive the right analgesic prescription. Comorbidities and polymedications may increase the risk of drug-drug interactions, therefore drug metabolism should be taken into account when selecting analgesic drugs. Automedication is common among HD patients but should be avoided to reduce the risk of hazardous drug administration. Further research is warranted to define the efficacy and safety of analgesic drugs and techniques in the context of patients with ESRD as generalizing information from studies conducted in the general population could be inappropriate and potentially dangerous. A multidisciplinary approach is recommended for the management of complex pain syndromes in frail patients, such as those suffering from ESRD.
疼痛是终末期肾病(ESRD)患者最常见的症状之一,但在血液透析(HD)患者中常常未被识别和充分治疗。充分疼痛管理的障碍包括对该问题认识不足、医学教育不足、对可能的药物相关副作用的担忧,以及对老年和 HD 患者疼痛不可避免的常见误解。在 HD 工作的护理人员应该意识到疼痛评估和管理不足可能带来的后果。HD 患者常见的疼痛综合征包括肌肉骨骼疾病和代谢性神经病,与典型的透析内疼痛相关。评估疼痛的病因、性质和强度对于选择正确的镇痛药至关重要。基于机制的疼痛管理方法可能会带来更好的结果。考虑到清除率改变和 ESRD 患者可能存在的毒性,药代动力学因素应指导正确的镇痛处方。合并症和多种药物治疗可能会增加药物相互作用的风险,因此在选择镇痛药时应考虑药物代谢。自动药物治疗在 HD 患者中很常见,但应避免,以降低危险药物给药的风险。需要进一步的研究来确定 ESRD 患者镇痛药物和技术的疗效和安全性,因为从一般人群中进行的研究中推广信息可能不恰当且潜在危险。建议采用多学科方法来管理脆弱患者(如 ESRD 患者)的复杂疼痛综合征。